Ensifentrine
Maintenance treatment of chronic obstructive pulmonary disease (COPD)
- CAS No.
- 298680-25-8
- Indication Class
- Respiratory
- Patent Expiry
- To be assessed
- Therapeutic Area
- Respiratory / COPD
- Target / Mechanism
- PDE3A·PDE3B·PDE4A·PDE4D·PDE4B·+more
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 6 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| 2-Chloro-9,10-dimethoxy-6,7-dihydro-4H-pyrimido[6,1-a]isoquinolin-4-one | 75535-96-5 | — | |
| 2,4,6-Trimethylaniline | 88-05-1 | — | |
| 2,4,6(1H,3H,5H)-Pyrimidinetrione, 1-(3,4-dimethoxyphenyl)- | 298680-49-6 | — | |
| 3,4-Dimethoxyphenethylamine | 120-20-7 | — | |
| 9,10-dimethoxy-2-(2,4,6-trimethylanilino)-6,7-dihydro-4H- pyrimido(6,1-a)isoquinolin-4-one | 76536-66-8 | — | |
| N-(2-Bromoethyl)phthalimide | 574-98-1 | — |
Listing Logic · Why It's Worth Listing
The first novel-mechanism inhaled COPD maintenance therapy in over a decade, combining bronchodilation and anti-inflammation, filling the gap after triple therapy.
Respiratory / COPD · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
6 key intermediates available; scale-up and cost control manageable
Product Description
Ensifentrine is a groundbreaking, first-in-class treatment for COPD. Uniquely targeting both the PDE3 and PDE4 pathways, it works by simultaneously opening airways (bronchodilation) and reducing lung inflammation with a single inhaled medicine. Approved by the FDA in June 2024, it is delivered directly to the lungs for targeted relief in adults with chronic obstructive pulmonary disease.
Supply source: Unibest · Ensifentrine, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.